Spots Global Cancer Trial Database for A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
Study ID: NCT04557098
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Detailed Description: Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope, Duarte, California, United States
University of California San Francisco, San Francisco, California, United States
Stanford University Medical Center, Stanford, California, United States
Winship Cancer Institute Emory University, Atlanta, Georgia, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Universitair Ziekenhuis Gent - UZ GENT, Gent, , Belgium
Universitaire Ziekenhuizen Leuven, Leuven, , Belgium
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
University Health Network UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
McGill University Health Centre, Montreal, Quebec, Canada
Peking University First Hospital, Beijing, , China
West China Hospital Si Chuan University, Chengdu, , China
Sun Yat -Sen University Cancer Center, Guangzhou, , China
First affiliated Hospital of Zhejiang University, Hangzhou, , China
Shanghai Changzheng Hospital, Shanghai, , China
Shengjing Hospital of China Medical University, Shenyang, , China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, , China
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, , China
Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez, Lille Cedex, , France
C.H.U. Hotel Dieu - France, Nantes, , France
Centre Hospitalier Lyon Sud, Pierre Benite, , France
CHRU Hôpital Jean Bernard, Poitiers, , France
Pôle IUC Oncopole CHU, Toulouse cedex 9, , France
CHRU Hôpital Bretonneau, Tours, , France
Universitaetsklinikum Heidelberg, Heidelberg, , Germany
Universitaetsklinikum Leipzig, Leipzig, , Germany
Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,, Tübingen, , Germany
Universitatsklinikum Wurzburg, Wuerzburg, , Germany
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, , Italy
Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi, Bologna, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, , Italy
VU Medisch Centrum, Amsterdam, , Netherlands
Hosp. Univ. Germans Trias I Pujol, Badalona, , Spain
Hosp. Clinic de Barcelona, Barcelona, , Spain
Hosp. Univ. 12 de Octubre, Madrid, , Spain
Clinica Univ. de Navarra, Pamplona, , Spain
Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcon, , Spain
Hosp. Clinico Univ. de Salamanca, Salamanca, , Spain
Hosp. Univ. Marques de Valdecilla, Santander, , Spain
Sahlgrenska University Hospital, Göteborg, , Sweden
Skane University Hospital, Lund, , Sweden
Haematology Centre, R 51, Stockholm, , Sweden
University College Hospital, London, , United Kingdom
University Hospital Southampton, Sothampton, , United Kingdom
Royal Marsden Hospital, Sutton, , United Kingdom
Contact Details
Name: Janssen Research & Development, LLC Clinical Trial
Affiliation: Janssen Research & Development, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
